Mariner LLC Buys 114,504 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Mariner LLC boosted its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 479.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 138,375 shares of the company's stock after acquiring an additional 114,504 shares during the quarter. Mariner LLC's holdings in Dr. Reddy's Laboratories were worth $2,185,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its stake in Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after acquiring an additional 1,507 shares during the last quarter. Glass Jacobson Investment Advisors llc boosted its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after acquiring an additional 1,600 shares in the last quarter. POM Investment Strategies LLC grew its position in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after acquiring an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Dr. Reddy's Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after purchasing an additional 2,093 shares in the last quarter. Finally, Allworth Financial LP raised its position in Dr. Reddy's Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after purchasing an additional 2,230 shares during the last quarter. Institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Down 0.5 %

Shares of Dr. Reddy's Laboratories stock traded down $0.08 on Tuesday, hitting $13.87. The stock had a trading volume of 186,578 shares, compared to its average volume of 1,463,956. The stock has a 50 day moving average of $13.18 and a 200 day moving average of $14.19. The firm has a market capitalization of $11.57 billion, a P/E ratio of 22.05 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Sell-side analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.